Critical Outcome Technologies to Present at the 12th Annual BIO Investor Forum

Critical Outcome Technologies Inc. (TSX VENTURE:COT) ("COTI" or the "Company"),
the bioinformatics and accelerated drug discovery company, announced today that
Dr. Wayne Danter, President & CEO, will be presenting at the 12th Annual BIO
Investor Forum
(http://www.bio.org/events/conferences/12th-annual-bio-investor-forum) on
Wednesday, October 9, 2013, at 9:30 a.m. PDT in San Francisco.


Dr. Danter will highlight the Company's innovative drug discovery platform
technology and two-pronged commercial validation and revenue strategy during the
live presentation. Dr. Danter will also be available to participate in
one-on-one meetings with investors who are registered to attend the conference.


An online investor kit, including the Company's investor presentation and fact
sheet, are available on the Company's corporate blog at
http://www.criticaloutcomeblog.com/investor-kit.html. 


Follow @CriticalOutcome and the official conference feed on Twitter, and join
the conversation by using #BIF13.


About Critical Outcome Technologies Inc. (COTI) 

COTI is a leading-edge technology company specializing in accelerating the
discovery and development of small molecules - dramatically reducing the time
and cost to bring new drugs to market. COTI'S proprietary artificial
intelligence system, CHEMSAS(R), utilizes a series of predictive computer models
to identify compounds with a high probability of being successfully developed
from disease specific drug discovery through chemical optimization and
preclinical testing. These compounds are targeted for a variety of diseases,
particularly those for which current treatments are either lacking or
ineffective.


For more information, visit www.criticaloutcome.com.

Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome 

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CEO
519-858-5157
wdanter@criticaloutcome.com
www.criticaloutcome.com


Heisler Communications
Trevor Heisler
Investor Relations
416-500-8061
trevor@heislercommunications.com

Cotinga Pharmaceuticals (TSXV:COT)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024